VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2018 | Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF

As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease. Here, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, discusses how different classes of genetic abnormalities in MM could be targeted. Dr Kaiser highlights exciting work on the t(4;14) translocation in MM and tissue agnostic therapies.This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter